RT Journal
A1 Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM
T1 INcreased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis
JF Archives of Dermatology
JO Archives of Dermatology
YR 2012
FD September 1
VO 148
IS 9
SP 995
OP 1000
DO 10.1001/archdermatol.2012.1401
UL http://dx.doi.org/10.1001/archdermatol.2012.1401
AB Objective 
                  To assess the risk of incident diabetes mellitus (DM) in patients with psoriasis and to evaluate DM treatment patterns among patients with psoriasis and incident DM.Design 
                  Population-based cohort study.Setting 
                  United Kingdom–based electronic medical records.Patients 
                  We matched 108 132 patients with psoriasis aged 18 to 90 years with 430 716 unexposed patients based on practice and time of visit. For our nested study, only patients who developed incident DM during our study time were included.Main Outcome Measures 
                  Incident DM and adjusted risk of pharmacotherapy among those with incident DM.Results 
                  The fully adjusted hazard ratios (95% CIs) for incident DM were 1.14 (95% CI, 1.10-1.18), 1.11 (95% CI, 1.07-1.15), and 1.46 (95% CI, 1.30-1.65) in the overall, mild, and severe psoriasis groups, respectively. Among those with incident DM and severe psoriasis, the adjusted risk for receiving DM pharmacotherapy was 1.55 (95% CI, 1.15-2.10).Conclusions 
                  Our results suggest that psoriasis is an independent risk factor for the development of type 2 DM in a dose-dependent manner, and that patients with severe psoriasis who develop DM are more likely to receive systemic diabetic therapies in comparison with patients with DM but without psoriasis.